Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces the three other members of its Scientific Advisory Board Committee headed by Professor Pierre Corvol who was appointed on July 8, 2014 (see press release).
The Scientific Advisory Board members are:
- Professor Pierre Corvol, President
Professor Emeritus, College de France and Honorary President of the College de France
- Professor John C.Burnett Jr
Professor of Medicine, Professor of Physiology, Mayo Clinic, Rochester (USA)
- Professor Mark Caulfield
Co-director of William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (UK)
- Professor Alexandre Persu
Head of Hypertension Consultation and Chef de Clinique in Cardiology, Catholic University of Louvain (Belgium)
The Scientific Advisory Board will take advantage of the expertise of these four recognised international scientists in cardiology to provide recommendations regarding the R&D programs of Quantum Genomics. In particular, it will give advice regarding the biomarkers that are relevant for hypertension regarding targeted (for example Low Renin High Vasopressin profile) or resistant patients and for congestive heart failure.
John C. Burnett Jr
Marriott Family Cardiovascular Research Professor, Mayo Clinic
Member, American Society for Clinical Investigation
Member, Association of American Physicians
John C. Burnett Jr., M.D., studies the endocrine role of the heart in cardiorenal homeostasis with a focus on the natriuretic peptides in heart failure, hypertension and myocardial infarction. His long-term goal is the engineering and clinical development of novel designer natriuretic peptides for the treatment of human cardiorenal disease, and the development of innovative natriuretic peptide-based diagnostics.
With continuous funding from the National Institutes of Health, Dr. Burnett and his team have developed three novel designer peptides currently in clinical trials targeting heart failure and resistant hypertension. From this work, seven patents have been awarded and three biotechnology companies founded.
Co-director of William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London (UK)
Director of the NIHR Biomedical Research Unit in Cardiovascular Disease at Barts (UK)
Member of the Academy of Medical Sciences in the UK
Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew's Hospital where he developed a research programme in molecular genetics of hypertension and clinical research. In 2009, he won the Lily Prize of the British Pharmacology Society. Since 2008, he directs the Barts National Institute of Health Research Cardiovascular Biomedical Research Unit. He was appointed Director of the William Harvey Research Institute in 2002 and elected to the Academy of Medical Sciences in 2008, and was President of the British Hypertension Society (2009-2011). He served on the NICE Guideline Group for hypertension.
Since 1996, he has been National Co-ordinator of the MRC British Genetics of Hypertension (BRIGHT) Study on behalf of 5 UK Universities. He was on the Steering Group of the Anglo-Scandinavian Cardiac Outcome Trial recruiting 1157 hypertensives.This trial has changed international guidance on lipid lowering and high blood pressure treatment. In 2007, 2009 and 2011 his research has been independently rated amongst the top ten scientific discoveries in his field.
Head of the Hypertension Clinic, Cardiology Department, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium
Member of the International and European Society of Hypertension
Alexandre Persu is professor of Medicine, specialist in Hypertension and Nephrology, head of the Hypertension outpatient clinic and Chef de Clinique in Cardiology at the Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium.
He is also secretary of the Belgian Hypertension Committee (BHC), member of the Editorial Board of the European Journal of Clinical Investigation and former member of the Editorial Board of the Journal of Hypertension.
Currently, his main research interests are resistant and secondary hypertension.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.
Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).
(+33) 1 60 13 76 80
CFO - Investor relations
(+33) 1 60 13 76 84
(33) 1 53 67 07 80
Powered by Actusnews Wire (press release services) ©